The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of April 30th, 2018:
- 46 negotiations are currently underway with 7 new files added since the last update of March 31st, 2018:
- Adlyxine (lixisenatide): Used to treat type 2 diabetes mellitus
- Ilaris (canakinumab): Used to treat systemic juvenile idiopathic arthritis
- Izba (travoprost): Used to treat open-angle glaucoma
- Renflexis (infliximab): Used to treat rheumatoid arthritis, ankylosing spondylitis, adult Crohn’s disease, pediatric Crohn’s disease, fistulising Crohn’s disease, adult ulcerative colitis, pediatric ulcerative colitis, psoriatic arthritis, plaque psoriasis
- Rexulti (brexpiprazole): Used to treat schizophrenia
- Tresiba (insulin degludec): Used to treat type 1 and type 2 diabetes mellitus
- Viacoram (perindopril arginine/amlodipine): Used to treat essential hypertension
- 208 joint negotiations have been completed with 1 new file added since the last update of March 31st, 2018:
- Kyleena (levonorgestrel): Used for the prevention of pregnancy
- 58 drug products for which there were no negotiations, with no new files added since the last update of March 31st, 2018.
- 13 negotiations for brand name drug products have been recommended by the pCPA to be considered by each Province/Territory individually with no new files added since the last update of March 31st, 2018.
For more information, please consult the pCPA’s website.